GENE ONLINE|News &
Opinion
Blog

Astellas Pharma
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
Japan’s Red Biotechnology and International Business Partnering Take Spotlight on BioJapan 2023
2023-11-03
GeneOnline’s Weekly News Highlights: Sept 4-Sept 8
2023-09-12
Astellas Withdraws Lawsuit Against IRA but Maintains Concerns
2023-09-11
Astellas Secures Licensing Agreement with 4D Molecular Therapeutics for Gene Therapy Vector Technology
2023-07-12
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
Astellas Trains Sights On Iveric Bio In $5.9 Billion Acquisition
2023-05-03
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Astellas Clears Primary Endpoints In Prostate Cancer And Menopause Trials
2023-03-14
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
2023-01-12
Astellas’ Zolbetuximab Meets Phase 3 Endpoints In Gastric And GEJ Cancers
2022-12-16
Astellas’ Claudin 18.2 Antibody Shows Its Teeth In GEJ Cancer Trial
2022-11-17
Astellas Invests $50 Million In Taysha, Licenses Two CNS Gene Therapies
2022-10-25
EMA Begins Regulatory Review For Astellas’ Fezolinetant
2022-10-03
Further Clinical Trial Results Reinforce Prior Findings For Astellas’ Menopause Treatment
2022-09-05
1 2 3
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top